Natco Pharma signs licensing deal with Lilly for Covid drug Baricitinib
Natco Pharma has signed a royalty-free, non-exclusive, voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and commercializing Baricitinib for the treatment of ... Read More
Torrent Pharma signs licensing deal with Lilly for Covid drug baricitinib
Torrent Pharmaceuticals (Torrent Pharma) has signed a licensing agreement with Eli Lilly and Company with an objective to bring the latter’s baricitinib for Covid-19 treatment ... Read More
Dr. Reddy’s Laboratories, Lilly sign deal for Covid-19 drug baricitinib
Dr. Reddy’s Laboratories said that it has forged a royalty-free, non-exclusive voluntary licensing agreement with US pharma giant Eli Lilly and Company (Lilly) for the ... Read More
Sun Pharma signs licensing deal with Lilly for Covid-19 drug baricitinib
Sun Pharmaceutical Industries (Sun Pharma) said that it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for expanding access to ... Read More
Lupin strikes deal with Lilly for Covid-19 drug Baricitinib in India
Lupin Limited said that it has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company (Lilly) for manufacturing and selling the ... Read More
Natco Pharma gets CDSCO nod for use of Baricitinib in Covid patients
Natco Pharma has secured emergency use approval for Baricitinib from India’s Central Drugs Standard Control Organization (CDSCO) for the treatment of Covid-19. The Indian pharma ... Read More
Eli Lilly completes $1.04bn acquisition of Prevail Therapeutics to expand gene therapy program
Eli Lilly and Company has officially finalized its acquisition of Prevail Therapeutics in a deal valued at up to $1.04 billion. This acquisition represents a ... Read More
Lilly to launch real-world Covid-19 study of bamlanivimab in New Mexico
Eli Lilly and Company (Lilly), a global leader in the pharmaceutical industry, has announced plans to conduct a new pragmatic study of its experimental Covid-19 ... Read More
Eli Lilly to acquire Prevail Therapeutics for $1.04bn, expanding gene therapy pipeline
Eli Lilly and Company has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a prominent US gene therapy company specializing in ... Read More
Lilly partners with UnitedHealth Group for pragmatic study of bamlanivimab in high-risk COVID-19 patients
Eli Lilly and Company (Lilly) has formed a strategic collaboration with UnitedHealth Group to conduct a pragmatic clinical study on bamlanivimab (LY-CoV555), a monoclonal antibody ... Read More